Table 4 Extent of mono- and combination drug therapy use in the male BPO sub-cohort
Monotherapy | N | % of monotherapy patients | % of all patients in BPO sub-cohort | % of all male patients |
|---|---|---|---|---|
Any BPO drug monotherapy | 29,739 | 100.0 | 81.9 | 61.1 |
Any alpha-blocker monotherapy | 27,462 | 92.3 | 75.6 | 56.4 |
Any 5-ARI monotherapy | 2277 | 7.7 | 6.3 | 4.7 |
Tamsulosin | 21,158 | 71.1 | 58.3 | 43.5 |
Doxazosin | 5456 | 18.3 | 15.0 | 11.2 |
Finasteride | 2131 | 7.2 | 5.9 | 4.4 |
Alfuzosin | 665 | 2.2 | 1.8 | 1.4 |
Dutasteride | 146 | 0.5 | 0.4 | 0.3 |
Prazosin | 101 | 0.3 | 0.3 | 0.2 |
Terazosin | 44 | 0.1 | 0.1 | 0.1 |
Indoramin | 38 | 0.1 | 0.1 | 0.1 |
Combination drug therapy | N | % of combination drug therapy patients | % of all patients in BPO sub-cohort | % of all male patients |
|---|---|---|---|---|
Any combination drug therapy | 6568 | 100.0 | 18.1 | 13.5 |
Any alpha-blocker + any 5-ARI | 5573 | 84.9 | 15.3 | 11.4 |
Finasteride + tamsulosin | 3262 | 49.7 | 9.0 | 6.7 |
Dutasteride + tamsulosin | 1189 | 18.1 | 3.3 | 2.4 |
Doxazosin + tamsulosin | 614 | 9.3 | 1.7 | 1.3 |
Doxazosin + finasteride | 289 | 4.4 | 0.8 | 0.6 |
Alfuzosin + finasteride | 233 | 3.5 | 0.6 | 0.5 |
Alfuzosin + tamsulosin | 208 | 3.2 | 0.6 | 0.4 |
Doxazosin + finasteride + tamsulosin | 167 | 2.5 | 0.5 | 0.3 |
Dutasteride + finasteride + tamsulosin | 125 | 1.9 | 0.3 | 0.3 |
Other combinations | 481 | 7.3 | 1.3 | 1.0 |
Drug class | N | % of all patients in BPO sub-cohort | % of all male patients |
|---|---|---|---|
Any BPO drug | 36,307 | 100 | 74.6 |
Any alpha-blocker | 33,984 | 93.6 | 69.8 |
Any 5-ARI | 7896 | 21.7 | 16.2 |